The Ede et al.’s study [50] described the preclinical and clinical studies that have been conducted to test the safety and efficacy of a cancer vaccine, the HER-vaxx (IMU-131), in the treatment of HER-2-expressing cancers (such as GC) (Table 2) [50]. Here, ERBB2 is linked to cancer.